Akero Therapeutics, Inc. (NASDAQ: AKRO)

This lawsuit is for anyone who acquired securities in Akero Therapeutics, Inc. (NASDAQ: AKRO) from September 13, 2022 through October 9, 2023.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by leading investors to believe that the FDA would likely approve the Company’s drug, EFX, for the treatment of non-alcoholic liver disease, without a reasonable basis for doing so considering that the Company was conducting clinical testing in a way that the FDA was unlikely to consider the results reliable.

On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Akero Therapeutics, Inc. (NASDAQ: AKRO) from September 13, 2022 through October 9, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.